Sangamo Therapeutics
Sangamo Therapeutics conducts clinical trials and collaborates with global pharmaceutical companies to develop genomic medicines, utilizing proprietary zinc finger technology. The company targets diseases such as Hemophilia A, Fabry Disease, Renal Transplantation, and Sickle Cell Disease, and offers an Expanded Access Policy for investigational drugs.
Services
Sangamo Therapeutics conducts clinical trials to evaluate the safety, tolerability, and potential efficacy of its genomic medicines. The company provides an Expanded Access Policy to offer investigational drugs to patients facing life-threatening or serious medical conditions without approved treatment options. Additionally, Sangamo participates in various scientific and medical conferences, presenting their findings and advancements in genomic medicine.
Collaborations with Pharmaceutical Companies
Sangamo Therapeutics collaborates with leading global pharmaceutical companies to extend the reach of its technology and accelerate the development of genomic medicines. These partnerships are crucial for advancing their pipeline programs and ensuring that innovative genomic treatments can reach broader markets effectively.
Pipeline Programs
Sangamo Therapeutics offers a robust pipeline of programs targeting diseases such as Hemophilia A, Fabry Disease, Renal Transplantation, and Sickle Cell Disease. These programs leverage their proprietary zinc finger technology and aim to address unmet medical needs in these critical areas. Each of these programs is in various stages of development, ranging from early research to clinical trials.
Zinc Finger Technology in Genomic Medicine
Sangamo Therapeutics utilizes proprietary zinc finger technology for its genomic medicine initiatives. This technology allows precise editing of the genome, which is fundamental to the development of their treatments. The zinc finger nucleases (ZFNs) enable targeted genome modification, offering potential therapeutic solutions for genetic disorders.
Bioethical Framework for Genomic Medicine
Sangamo Therapeutics engages in the development of a bioethical framework to guide the use of genomic medicine. This framework ensures that the company's technological advancements in genome editing are conducted responsibly and ethically. The commitment to bioethics is a critical aspect of their operations, reflecting their dedication to patient safety and ethical standards in genomic research.